

# Nuevolution A/S

Rønnegade 8  
2100 Copenhagen Ø

CVR-nr. 26 02 97 08

## Annual Report for 2020

Approved at the annual general meeting of shareholders

on 28 June 2021

---

Chairman: Tore von Würden Petersen

## Table of content

	Page
Company data	3
Management's review	4
Directors' and Management's Statement on the Annual Report	5
Independent Auditors' Report	6-8
Income statement	9
Balance Sheet	10
Statement of changes in equity	11

## Notes

General notes	
1 Accounting policies	12-19
Income statement	
2 Revenue	20
3 Research and development expenses	20
4 Sales, general and administration expenses	20
5 Staff expenses	20
6 Other operating income	21
7 Tax on result for the year and deferred tax	21
Financial position	
8 Tangible fixed assets	21
9 Share capital	22
10 Lease liabilities	22
Other disclosures	
11 Contingent assets and liabilities	23
12 Significant events after the balance sheet date	23
13 Funding and Going Concern	23

## Company data

Company	Nuevolution A/S Rønnegade 8, 5. 2100 Copenhagen Ø
Telephone	+45 70 20 09 87
WEB	<a href="http://www.amgen.com">www.amgen.com</a>
e-mail:	
CVR no.:	26 02 97 08
Financial year	1 January - 31 December 2020
Board of Directors	Tore von Würden Petersen, Chairman Birgitte Karen Claudius Morten Kjærgaard Jakobsen
Executive Management	Alex Haahr Gouliaev
Parent Company	Nuevolution AB c/o Amgen Akiebolag Box 706 169 27 Solna Sweden
Telephone	+45 70 20 09 87
Org. No.	559026-4304
Ownership	100%
Ultimate parent	Amgen Inc. One Amgen Center Drive Thousand Oaks, CA USA
Telephone	+1 805-447-1000
	<a href="http://www.amgen.com">www.amgen.com</a>
Shareholders meeting	28 June 2021
Auditor	EY Godkendt Revisionspartnerselskab Dirch Passers Allé 36 2000 Frederiksberg
Bank	Citibank Europe Plc, Denmark Branch, Filial of Citibank Europe Plc, Irland Vesterbrogade 1 L 1620 Copenhagen V

## Management's Review

### Activities

Nuevolution A/S is a Danish biopharmaceutical company focused on developing drug treatments for human disease within oncology and chronic inflammatory diseases.

Nuevolution A/S is the inventor of Chemetics<sup>®</sup>, a patent protected drug discovery platform, which enables efficient discovery of novel small molecule (tablet based) drug candidates.

The Chemetics<sup>®</sup> platform provides access to screening of trillions of molecules and efficient optimization of drug properties in the process of identifying the drug candidate.

Our efforts are leveraged by a proven and highly efficient drug discovery engine, and backed by a skilled and dedicated team of employees, world-class academic and corporate expert advisers catalyzing our ambition to deliver new medicines to patients.

### Development in activities and financial matters

The result for the financial year 2020 shows a loss of TDKK 33,490 compared to loss of TDKK 76,305 for the financial year 2019. Management considers the result to be satisfactory.

In December 2020, Amgen has obtained all rights to the continued development of the RORgt program that was previously in collaboration with Almirall.

### Covid-19

Nuevolution A/S has experienced a partial lock-down during the period March 12 2020 until today with some impact on laboratory access. The access has throughout the period gradually increased with a setback in January 2021. We are now at 100% laboratory access. Office personnel have had their work places mainly at home. It has not meant any major loss in efficiency. Some materials have been scarce, but it has been possible to obtain materials without any major impact on productivity.

### Going concern

As set out in note 13 the company has obtain a letter of financial support from Amgen Global Finance BV to support its operations at least through the end of 2021, hence we have presented the financial statements under the going concern assumption.

### Subsequent events

In first half of 2021 the company has obtain a credit facility from Amgen Global Finance BV to secure its operation to the end of 2021.

No other subsequent event with significant effect on the annual report for 2020 has occurred after the balance sheet date.

## **Directors' and Management's Statement on the Annual Report**

The Board of Directors and Executive Board have today discussed and approved the annual report of Nuevolution A/S for the financial year 1 January to 31 December 2020.

The annual report has been prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2020 and of the results of its operations for the financial year 1 January – 31 December 2020.

Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.

We recommend that the annual report be approved at the annual general meeting.

Copenhagen, 28 June 2021

### **EXECUTIVE MANAGEMENT**

Alex Haahr Gouliaev  
CEO

### **BOARD OF DIRECTORS**

Tore von Würden Petersen  
Chairman of the Board

Birgitte Karen Claudius

Morten Kjærgaard Jakobsen

## Independent auditors' report

### To the shareholder of Nuevolution A/S

#### Opinion

We have audited the financial statements of Nuevolution A/S for the financial year 1 January – 31 December 2020, which comprise income statement, balance sheet and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2020 and of the results of the Company's operations for the financial year 1 January – 31 December 2020 in accordance with the Danish Financial Statements Act.

#### Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Independence

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements.

#### Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

#### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

## Independent auditors' report

As part of an audit conducted in accordance with ISAs and additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- ▶ Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
- ▶ Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- ▶ Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- ▶ Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- ▶ Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

### Statement on the Management's review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

## Independent auditors' report

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the Management's review.

Copenhagen, 28 June 2021

EY Godkendt Revisionspartnerselskab

CVR no. 30 70 02 28

Rasmus Bloch Jespersen

State Authorised

Public Accountant

mne35503



**Income statement for the period 1 January - 31 December**

DKK '000	Note	2020	2019
Revenue	2	37.024	17.360
Research and development expenses	3, 5, 8	-81.650	-80.202
Sales, general and administrative expenses	4, 5, 8	-8.684	-16.345
<b>Operating expenses</b>		<b>-90.334</b>	<b>-96.547</b>
Other operating income	6	189	285
<b>Operating result</b>		<b>-53.121</b>	<b>-78.902</b>
Financial income		0	298
Financial expenses		-1.101	-923
<b>Result before tax</b>		<b>-54.222</b>	<b>-79.527</b>
Corporate income tax	7	20.732	3.222
<b>Result for the period</b>		<b>-33.490</b>	<b>-76.305</b>
<b>Recommended appropriation of the period's result</b>			
Retained earnings		-33.490	-76.305
<b>Total appropriation of the period's result</b>		<b>-33.490</b>	<b>-76.305</b>

## Balance Sheet

DKK '000	Note	31 December 2020	31 December 2019
<b>ASSETS</b>			
<b>Non-current assets</b>			
Other fixtures, fittings, tool and equipment	8	6.537	2.365
Right-of-use-assets	8	8.441	12.183
Leasehold improvement	8	2.148	1.009
Assets under construction	8	13.762	0
Income tax receivable	7	0	1.889
Leasehold deposits		1.328	1.325
<b>Total non-current assets</b>		<b>32.216</b>	<b>18.771</b>
<b>Current assets</b>			
Trade receivable		0	226
Income tax receivable	7	7.930	5.500
Deferred tax assets	7	14.691	0
Other current receivables and prepayments		1.585	2.037
Receivables, Group Companies		65.948	2.390
Cash and cash equivalents		0	6.640
<b>Total current assets</b>		<b>90.154</b>	<b>16.793</b>
<b>TOTAL ASSETS</b>		<b>122.370</b>	<b>35.564</b>
<b>EQUITY AND LIABILITIES</b>			
Share capital	9	16.500	16.500
Share premium		285.395	184.233
Retained earnings		-232.416	-198.926
<b>Total shareholders' equity</b>		<b>69.479</b>	<b>1.807</b>
Lease liabilities	10	5.933	8.914
<b>Total non-current liabilities</b>		<b>5.933</b>	<b>8.914</b>
<b>Current liabilities</b>			
Current portion of long-term lease liabilities	10	3.093	3.513
Trade payables		14.568	2.377
Payables, Group Company		285	0
Other current liabilities		26.253	16.930
Prepayments from collaboration partners		2.759	2.023
<b>Total current liabilities</b>		<b>46.958</b>	<b>24.843</b>
<b>Total liabilities</b>		<b>52.891</b>	<b>33.757</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>122.370</b>	<b>35.564</b>

## Statement of changes in equity

DKK '000	Share capital	Share premium	Retained Earnings	Total equity
<b>Equity at 1 January 2020</b>	16.500	184.233	-198.926	1.807
Result for the period	0	0	-33.490	-33.490
Capital contribution	0	101.162	0	101.162
<b>Equity at 31 December 2020</b>	<b>16.500</b>	<b>285.395</b>	<b>-232.416</b>	<b>69.479</b>

There are no limitations concerning distribution of share premium account.

## Note 1: Accounting policies

The Annual Report for the Company has been prepared in accordance with the Danish Financial Statement Act and Danish disclosure requirements for annual reports for accounting class B entities and elective choice of certain provisions applying to reporting class C entities.

The Annual Report is presented in DKK. All values are rounded to the nearest thousand DKK.

Effective from the financial year 2020, the Company has implemented amending act no. 1716 of 27 December 2018 to the Danish Financial Statements Act. The implementation of the amending act has not affected the Company's accounting policies on recognition and measurement of assets and liabilities but has solely entailed a requirement for further disclosures. The accounting policies used in the preparation of the financial statements are consistent with those of last year.

The ultimate parent of the company is Amgen Inc. The consolidated financial statement of Amgen Inc. can be acquired at <https://investors.amgen.com/financials/annual-reports>.

### FOREIGN CURRENCY TRANSLATION

On initial recognition, foreign currency transactions are translated at the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rate at the transaction date and the rate at the date of payment are recognised in the income statement as financial income or financial expenses. Receivables, liabilities and other monetary items denominated in foreign currency that have not been settled at the balance sheet date are translated at closing rates. Foreign exchange differences between the rate of exchange at the date of the transaction and the rate of exchange at the date of payment or the balance sheet date, respectively, are recognised in the income statement under financial items.

### Income statement

#### Revenue

The Company has chosen IFRS 15 as interpretation for revenue recognition.

Revenue comprises the fair value of the consideration received or receivable for sales of exclusive license rights and income derived from contract research and other services. Revenue is measured net of discounts, value added tax, duties, etc. collected on behalf of a third party.

In determining the appropriate amount of revenue to be recognized as it fulfils its obligations under each of its agreements, the company performs the following five steps:

- (i) identification of the promised services in the contract;
- (ii) determination of whether the promised services are performance obligations including whether they are distinct in the context of the contract;
- (iii) measurement of the transaction price, including the constraint on variable consideration;
- (iv) allocation of the transaction price to the performance obligations; and
- (v) recognition of revenue when (or as) the company satisfies each performance obligation.

As part of the accounting for these arrangements, the company must develop assumptions that require judgement to determine the stand-alone selling price for each performance obligation identified in the contract. The company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenue, development timelines, and probabilities of technical and regulatory success.

#### *Licenses of Intellectual Property*

If the license to the company's intellectual property is determined to be distinct from the other performance obligations identified in an out-licensing arrangement, the company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the

licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

#### ***Milestone Payments***

At the inception of each arrangement that includes development milestone payments, the company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment.

#### ***Contract work***

Revenue from contract research and licenses that do not transfer the right of ownership to an intangible asset are recognized over time in line with the execution and transfer of the services. The percentage of completion is made up based on the stage of completion on each individual work in progress.

#### ***Significant License and Collaboration Agreements***

##### **Amgen**

In October 2016, Nuevolution entered into a research collaboration with Amgen, a multi target research collaboration in which Amgen has an exclusive option to obtain all rights to successfully developed programs.

During early discovery stage, Nuevolution covers all own cost. When Amgen decides to make a contractual opt-in, they will take over all cost including Nuevolution's cost. At contractual licensing, Amgen obtains ownership of the program and pays an upfront licensing fee of minimum USD 10 million depending on development stage at licensing. Further development and sales milestones equal up to USD 400 million per program plus tiered royalties on generated sales in case milestones are successfully reached.

Following the opt-in Nuevolution is reimbursed for all cost incurred on a non-refundable basis, why revenue is recognized in full as cost are incurred and invoiced. Future potential milestone payments including potential license of programs are outside the company's control why no revenue has been recognized.

##### **Janssen Biotech**

In October 2015, Nuevolution entered into a multitarget collaboration with Janssen Biotech, Inc.

Within the framework of the collaboration, Nuevolution will apply its drug discovery platform Chemetics® to discover and advance drug candidates against drug targets of interest to Janssen. Under the terms of the agreement, Nuevolution will receive an upfront payment, research funding and will be eligible to milestone payments upon achievement of specified research, development and commercial milestones. In addition, Nuevolution will be entitled to receive certain royalty payments on net-sale of products that may be commercialized as a result of the collaboration.

Future potential milestone payments are outside the company's control why no revenue has been recognized.

For the year ended 31 December 2020, Nuevolution has not recognized any revenues from future payments under the collaboration agreement with, Amgen or Janssen.

### **Research and development expenses**

Research and development expenses are incurred in the Company for in-house research and development activities as well as numerous research and development collaborations and alliances with third parties.

Research and development expenses mainly comprise the costs for active ingredient discovery, clinical studies, research and development activities in the areas of application technology and engineering, field trials, patents, regulatory approvals and approval extensions. In addition, research and development expenses also include wages and salaries, and other employee related cost, cost of premises, lawyer, depreciation etc. related to the research and development staff.

For accounting purposes, research expenses are defined as costs incurred for current or planned investigations undertaken with the prospect of gaining new scientific or technical knowledge and understanding. Development expenses are defined as costs incurred for the application of research findings or specialist knowledge to plans or designs for the production, provision or development of new or substantially improved products, services or processes, respectively, prior to the commencement of commercial production or use.

Development expenses that are directly attributable to the development of identifiable assets controlled by the company are reported as intangible assets when the following criteria are met:

- 1) It is technically possible to complete the intangible asset so that it can be used or sold
- 2) The company's intention is to complete the asset and to use or sell it
- 3) There are prerequisites to use or sell the asset
- 4) It can be shown how the asset can generate probable future economic benefits
- 5) Appropriate technical, financial and other resources to complete the development and to use or sell the asset are available
- 6) expenses that are attributable to assets during its development can be reliably calculated

Reimbursed expenses related to project under collaboration agreements are invoiced to the partners and are set-off against research and development expenses.

All research and development expenses are recognized in the income statement in the period in which they incur.

### **Sales, General and administrative expenses**

Sales, general and administrative expenses include wages and salaries, and other personnel related expenses, office costs, cost of premises, audit, lawyer, depreciation etc. related to management, sales, human resources, information technology, and the finance departments.

### **Staff expenses**

#### *Staff costs*

Staff expenses comprise of wages and salaries for staff engaged in research, development, sales, marketing, administration and management. The item also comprises all staff-related costs.

#### *Short-term remuneration*

Remuneration of employees in form of salaries, bonuses, paid vacation, paid sickness absence, etc. and pension are recognized when the relevant services are received.

### *Retirement benefit*

Post-employment pension and other remuneration are classified as defined-contribution or defined-benefit pension plans. The company has only defined-contribution pension plans. For defined-contribution plans, the company pays fixed contribution to a separate, independent legal entity and does not have any obligation to pay additional contribution. The company's earnings are charged with expenses in line with the benefits being earned, which normally coincides with the time when the premium is paid.

### **Other Operating income**

Other operating income comprises research funding from government grant. Research funding is recognized in the period when the research activities have been performed and when there is reasonable assurance that the grants will be received. Grants for research and development costs, which are recognized directly in the income statement are recognized under other operating income as the grants are considered to be cost refunds and not as such revenue.

Prepaid grants are recognized in the balance sheet as prepayments of government grants at par value on receipt and is transferred to the income statement concurrently with the related expenses occur.

### **Financial Income**

Financial income include interest income, realized and unrealized gains on transactions in foreign currencies. Financial income are recognized in the income statement at the amounts that relate to the reporting period.

### **Financial Expenses**

Financial expenses include interest expenses, interest expenses relating to finance lease payments, bank fees or alike and realized and unrealized losses on transactions in foreign currencies. Financial interest expenses are recognized in the income statement according to the effective interest method and other financial expenses are recognized in the income statement at the amounts that relate to the reporting period.

### **Income taxes**

Tax for the year, which includes current tax on the year's taxable income and the year's deferred tax adjustments, is recognized in the income statement as regards the portion that relates to the net result for the year and is taken directly to equity as regards the portion that relates to entries directly in equity or other comprehensive income, respectively.

In assessing current tax for the year, the applicable tax rates and legislation on the statement of financial position date are used. Nuevolution A/S has a corporate income tax year running from 1 July to 30 June. With effect from 16 July 2019 Nuevolution A/S entered a joint taxation group with Amgen Filial af Amgen Aktiebolag, Sweden, with Amgen Filial af Amgen Aktiebolag, Sweden as the administration company. At the same time Nuevolution A/S changed its tax year to follow the calendar year with the period 1 July 2019 to 31 December 2020 as transition period. The first joint taxation period is 16 July 2019 to 31 December 2020.

The company recognizes tax credits relating to research and development costs in accordance with the Danish corporate tax act at the corporate income tax rate (22% for both 2020 and 2019) based on total research and development cost of up to DKK 25 million.

In assessing current tax for the year, the applicable tax rates and legislation on the statement of financial position date are used.

### *Income tax receivable*

Current tax assets for the current and prior periods shall be measured at the amount expected to be recovered from the taxation authorities, using the tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period. Tax assets that is expected to be recovered within

12 months is reported as current income tax receivable and tax assets that is expected to be recovered after 12 month is reported as non-current income tax receivable.

#### *Deferred taxes*

Deferred tax is measured according to the statement of balance sheet liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. The deferred tax is stated based on the planned utilization of the individual asset and the settlement of the individual liability, respectively.

Deferred tax assets, including the tax value of tax losses carry-forward, are recognized in the balance sheet at the value at which they are expected to be utilized, either through elimination against tax on future earnings or through a set-off against deferred tax liabilities.

#### Deferred tax asset

Deferred tax assets, including the tax value of losses carried forward is recognized at the value as it is expected to be utilized, either by future earing or form the joint taxation with its Danish affiliated company.

### **Balance sheet**

#### **Tangible fixed assets**

##### *Tangible fixed assets*

Tangible fixed assets are measured at cost less accumulated depreciation and impairment losses.

Leased tangible fixed assets qualifying for assets held under finance lease contracts are measured as acquired fixed assets. The Management has assessed that the purchase option will be utilized.

Cost comprises the purchase price, costs directly allocated to the acquisition, and costs for preparation until the date when the asset is available for use.

Cost of assets held under finance lease contracts are measured as the lower of fair value and the present value of future lease payments, calculated on the internal discount rate.

Depreciation is calculated on a straight-line basis based on the following expected useful life:

	Year
Leasehold improvements	5-10
Other fixtures and fittings, tools and equipment	3-5

The residual value is determined at the time of acquisition and are reassessed every year. Where the residual value exceeds the carrying amount of the asset, no further depreciation charges are recognized. In case of changes in the residual value, the effect on the depreciation charges is recognized prospectively as a change in accounting estimates.

The Company accounts for leases in accordance with IFRS 16 Leases. The Company determines if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The lease liabilities are initially measured at the present value of the unpaid lease payments at the lease commencement date. Estimates and judgments include how the Company determined the discount rate it uses to discount the unpaid lease payments to present value, lease term and lease payments.

IFRS 16 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. For leases that do not provide an implicit rate, the Company uses the incremental borrowing rate based on the information available at



commencement date in determining the present value of lease payments. The Company's incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms.

The lease term includes the non-cancellable period of the lease plus any additional periods covered by a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise.

Lease payments included in the measurement of the lease liability comprise the following: fixed payments (including in-substance fixed payments), less any lease incentives paid or payable to the lessee, variable payments that depend on an index or rate, amounts expected to be payable under a residual value guarantee and the exercise price of the Company option to purchase the underlying asset if the Company is reasonably certain to exercise.

The ROU asset is initially measured at cost, which comprises the initial measurement of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred, less any lease incentives received.

The Company monitors for events or changes in circumstances that require a reassessment of a lease. When a reassessment results in the remeasurement of a lease liability, a corresponding adjustment is made to the carrying amount of the corresponding ROU asset unless doing so would reduce the carrying amount of the ROU asset to an amount less than zero. In that case, the amount of the adjustment that would result in a negative ROU asset balance is recorded in the income statement.

The Company has elected not to recognize ROU assets and lease liabilities for all short-term leases that have a lease term of 12 months or less. The Company recognizes the lease payments associated with its short-term leases as an expense on a straight-line basis over the lease term.

#### *Impairment of fixed assets*

Fixed assets are reviewed at the statement of financial position date to determine whether there are any indications of impairment. Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.

### **Trade receivables**

#### *Receivables*

Receivables from collaboration partners and other receivables are designated as receivables and are initially measured at fair value or transaction price and subsequently measured in the balance sheet at amortized cost, which generally corresponds to nominal value less expected provision for credit loss. This is consistent with prior periods classification.

#### *Impairment*

The Company has chosen IFRS 9 as interpretation for impairment write-down of financial receivables.

The Company records an allowance for expected credit losses for all loans and other debt financial assets not held at fair value through profit and loss. Expected credit losses are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive.

For receivables with collaboration partners and other receivables, the Company has applied the standard's simplified approach and has calculated expected credit losses based on lifetime expected credit losses. No provision for expected credit losses have been recognized given that the Company has not recognized any

of credit losses over the past financial years and do not expect to incur such. As the contract assets relate to the partnerships, the credit risk is based on an individual assessment.

### **Other current receivables and pre-payments**

Other current receivables and prepayments are measured at fair value, and subsequently at amortized cost using the effective interest method less impairment.

Prepayments recognized under assets comprise expenses incurred relating to subsequent financial periods. Prepayments are measured at cost.

### **Cash and cash equivalents**

Cash and cash equivalents comprise bank balances.

Balances in the group's cash pool scheme are not, due to the nature of the scheme, considered cash, but are recognized under 'Receivables, Group Companies' or 'Payables, Group Companies', as applicable.

### **Trade payables and other current liabilities**

Trade creditors are measured at fair value, and subsequently at amortized cost using the effective interest method. Carrying amount for Trade creditor is presumed to correspond to the fair value since it is by nature short-term.

Other liabilities are measured at amortized cost, which usually corresponds to the nominal value.

Present value adjustment is not performed since the duration is short.

Other current liabilities include a liability regarding frozen holiday payment of DKK 6.1 million (2019: DKK 1.9 million). The company expect to pay the obligation in 2021. Hence the obligation is recognized as other current liability.

### **Lease liabilities**

Lease obligations regarding right-to-use assets are recognized in the statement of financial position as liabilities and measured, at the inception of the lease, at the lower present value of future lease payments, calculated by reference to the interest rate implicit in each lease.

On subsequent recognition, lease liabilities are measured at amortized cost.

### **Contingent assets and liabilities**

Contingent assets and liabilities are assets and liabilities that arose from past events but whose existence will only be confirmed by the occurrence or non-occurrence of future events that are beyond Nuevolution's control.

Contingent assets and liabilities are not to be recognized in the financial statements but are disclosed in the notes.

### *Taxes*

Current tax payables and receivables are recognized in the balance sheet as the estimated income tax change for the year, adjusted for prior-year taxes and tax paid on account.

Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and tax base of assets and liabilities. However, deferred tax is not recognized on temporary differences relating to goodwill which is not deductible for tax purposes and on office premises and other items here temporary differences, apart from business combinations, arise at the date of acquisitions without affecting either profit/loss for the year or taxable income. Where alternative tax rules can be applied to determine the tax base, deferred tax is measured based on Management's intended use of the asset or settlement of the liability, respectively.

Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallize as current tax. Deferred tax assets are recognized at the expected value of their utilization; either as a set-off against deferred tax liabilities in the same legal tax entity. Changes in deferred tax due to changes in the tax rate are recognized in the income statement.

### **Significant events after the balance sheet date**

If Nuevolution obtains information after the balance sheet date, but prior to the date of the Board of Director's approval of the financial statements, about conditions that existed at the balance sheet date, Nuevolution assesses if the information affects the amounts that it recognizes in the financial statements.

Nuevolution will adjust the amounts recognized in its financial statements to reflect any adjusting events after the balance sheet date and update the disclosures that relate to those conditions in the light of the new information.

For non-adjusting events after the balance sheet date, Nuevolution will not change the amounts recognized in its financial statements but will disclose the nature of the non-adjusting event and an estimate of its financial effect, or a statement that such an estimate cannot be made, if applicable.

## Note

### 2 Revenue

DKK '000	2020	2019
Milestone payments (at a point in time)	0	7.462
Contract work (transferred over time)	37.024	9.898
<b>Total</b>	<b>37.024</b>	<b>17.360</b>

### 3 Research and development expenses

DKK '000	2020	2019
Employee benefit expenses	56.711	49.002
External expenses	27.981	29.992
Depreciation	4.783	3.835
<b>Total</b>	<b>89.475</b>	<b>82.829</b>
Reimbursed expenses from collaboration partners	-7.825	-2.627
<b>Net research and development expenses</b>	<b>81.650</b>	<b>80.202</b>

### 4 Sales, general and administration expenses

DKK '000	2020	2019
Employee benefit expenses	7.425	11.161
External expenses	884	4.813
Depreciation	375	371
<b>Total</b>	<b>8.684</b>	<b>16.345</b>

### 5 Staff expenses

DKK '000	2020	2019
Wages & salaries	41.101	38.962
Bonus	16.726	15.983
Pension (Defined contribution)	5.071	2.863
Other social security costs	266	319
Other personnel costs	972	2.036
<b>Total</b>	<b>64.136</b>	<b>60.163</b>

#### Staff costs are recognized as follows:

Research and development expenses	56.711	49.002
Sales, general and administration expenses	7.425	11.161
<b>Total staff cost</b>	<b>64.136</b>	<b>60.163</b>

#### Number of employees:

Average number of FTE	54	49
Number of FTE end of year	52	51

Members of the management have contracts of employment containing standard terms for management members of Danish companies, including the periods of termination notice that both parties are required to give and competition clauses. If a contract of employment of a member of the company's management is terminated by the company without misconduct on the part of such member, the member of the company's management is entitled to compensation, which, depending on the circumstances, may amount to a maximum of 8-12 months' remuneration.

## Note

### 6 Other operating income

DKK '000	2020	2019
Government grant	189	285
<b>Total</b>	<b>189</b>	<b>285</b>

### 7 Corporate income tax

DKK '000	2020	2019
Utilization of Danish Tax Credit	3.611	4.639
Tax paid in Spain	0	-1.417
Contribution from joint taxation	2.430	0
Changes in deferred tax asset	14.691	0
	<b>20.732</b>	<b>3.222</b>

The company has in previous years generated tax losses. As it is still uncertain whether deferred tax assets can be utilized beside expected utilization of tax losses carried forward from the joint taxation, no further assets has been recognized in the annual report. Deferred tax assets not recognized for 2020 were TDKK 132,879 (2019: TDKK 135,754).

According to current tax legislation, tax loss carry-forward can be carried forward indefinitely.

### 8 Tangible fixed assets

DKK '000	Other fixtures, fittings, tool and equipment	Right-of-use- assets	Leasehold improvement	Assets under construction	Total
Cost at 1 January 2020	22.413	18.241	10.703	0	51.357
Additions	5.296	0	1.431	13.762	20.489
<b>Cost at 31 December 2020</b>	<b>27.709</b>	<b>18.241</b>	<b>12.134</b>	<b>13.762</b>	<b>71.846</b>
Depreciation and impairment at 1 January 2020	20.048	6.058	9.694	0	35.800
Depreciation and impairment for the year	1.124	3.742	292	0	5.158
<b>Depreciation and impairment at 31 December 2020</b>	<b>21.172</b>	<b>9.800</b>	<b>9.986</b>	<b>0</b>	<b>40.958</b>
<b>Carrying amount at 31 December 2020</b>	<b>6.537</b>	<b>8.441</b>	<b>2.148</b>	<b>13.762</b>	<b>30.888</b>

Depreciation and impairment expenses are recognized as follows:

Research and development expenses	1.120	3.398	265	0	4.783
Sales, general and administration expenses	4	344	27	0	375
<b>Total depreciation and impairment expenses</b>	<b>1.124</b>	<b>3.742</b>	<b>292</b>	<b>0</b>	<b>5.158</b>

## Note

### 9 Share capital

	Share Capital	
	No. of shares	DKK '000
Balance at 1 January 2020	16.500.000	16.500
<b>Balance at 31 December 2020</b>	<b>16.500.000</b>	<b>16.500</b>
Balance at 1 January 2019	16.500.000	16.500
<b>Balance at 31 December 2019</b>	<b>16.500.000</b>	<b>16.500</b>

The share capital consists of 16.500.000 shares of DKK 1 nominal value. The share capital is fully paid up. All shares are owned by Nuevolution AB, Solna, Sweden.

### 10 Lease liabilities

The Company has entered leases for various items of tangible assets. Futures minimum lease payments under leases together with the present value of the net minimum lease payments are as follows:

DKK '000	31 December 2020	31 December 2019
Non-current lease liabilities	5.933	8.914
Current portion of long-term lease liabilities	3.093	3.513
<b>Total</b>	<b>9.026</b>	<b>12.427</b>

#### Lease obligations

DKK '000	31 December 2020		31 December 2019	
	Minimum payments	Present value of payments	Minimum payments	Present value of payments
0-1 year	3.281	3.093	3.786	3.513
1-2 years	3.025	2.909	3.169	2.981
2-5 years	3.069	3.024	6.095	5.933
> 5 years	0	0	0	0
<b>Total minimum lease payments</b>	<b>9.375</b>	<b>9.026</b>	<b>13.050</b>	<b>12.427</b>
Less amounts representing finance charges	349	0	623	0
<b>Total</b>	<b>9.026</b>	<b>9.026</b>	<b>12.427</b>	<b>12.427</b>

The company has entered into rent contracts, which all can be terminated at maximum of 6 months notice. Annual rent payment of TDKK 2,927 (2019: TDKK 2,887), where TDKK 2,658 (2019: TDKK 2,512) is included in research and development expenses and TDKK 269 (2019: TDKK 375) is included in sales, general and administrative expenses.

## Note

### 11 Contingent assets and liabilities

#### *License and Collaboration Agreements*

We are entitled to potential milestone payments and royalties on successful commercialization of product developed under license and collaboration agreements with our collaboration partners. Since the size and timing of such payments are uncertain until the milestones are reached, the agreements may qualify as contingent assets and, accordingly, no such assets have been recognized.

#### *Disputes*

The Company may, from time to time and within the framework of its operations, become involved in disputes and other legal proceedings. Currently no disputes or other legal proceedings exists.

#### *Joint taxation*

Since July 16, 2019 the company is jointly taxed with other Danish subsidiaries and Branches of Amgen Inc. The Company has unlimited joint and several liability for payment of Danish corporation taxes within the joint taxation.

### 12 Significant events after the balance sheet date

In first half of 2021 the company has obtain a credit facility from Amgen Global Finance BV to secure its operation to the end of 2021.

No other subsequent event with significant effect on the annual report for 2020 has occurred after the balance sheet date.

### 13 Funding and Going Concern

In October 2016, Nuevolution entered into a research collaboration with Amgen, a multi target research collaboration in which Amgen has an exclusive option to obtain all rights to successfully developed programs.

During early discovery stage, Nuevolution covers all own cost. When Amgen decides to make a contractual opt-in, they will take over all cost including Nuevolution's cost related to the respective opt-in programs. Following the opt-in Nuevolution is reimbursed for all cost incurred on a non-refundable basis. Future potential milestone payments including potential license of programs are outside the company's control why no revenue has been recognized.

As set out in note 12 the company has obtained a letter for financial support from Amgen Global Finance BV to support its operations at least through the end of 2021, hence the financial statements are presented under the going concern assumptions.

# Penneo

Underskrifterne i dette dokument er juridisk bindende. Dokumentet er underskrevet via Penneo™ sikker digital underskrift. Underskrivernes identiteter er blevet registeret, og informationerne er listet herunder.

“Med min underskrift bekræfter jeg indholdet og alle datoer i dette dokument.”

## Alex Haahr Gouliaev

CEO

På vegne af: Nuevolution A/S

Serienummer: PID:9208-2002-2-875322934371

IP: 198.176.xxx.xxx

2021-06-29 12:03:30Z

NEM ID 

## Tore von Würden Petersen

Chairman

På vegne af: Nuevolution A/S

Serienummer: PID:9208-2002-2-374899435320

IP: 212.178.xxx.xxx

2021-06-29 12:28:07Z

NEM ID 

## Tore von Würden Petersen

Board of Directors

På vegne af: Nuevolution A/S

Serienummer: PID:9208-2002-2-374899435320

IP: 212.178.xxx.xxx

2021-06-29 12:28:07Z

NEM ID 

## Birgitte Karen Claudius

Board of Directors

På vegne af: Nuevolution A/S

Serienummer: PID:9208-2002-2-478574038073

IP: 198.176.xxx.xxx

2021-06-29 13:04:06Z

NEM ID 

## Morten Kjærgaard Jakobsen

Board of Directors

På vegne af: Nuevolution A/S

Serienummer: PID:9208-2002-2-111922750165

IP: 198.176.xxx.xxx

2021-06-29 13:06:45Z

NEM ID 

## Rasmus Jespersen

State Authorised Public Accountant

På vegne af: EY Godkendt Revisionspartnerselskab

Serienummer: CVR:30700228-RID:34311459

IP: 145.62.xxx.xxx

2021-06-29 13:48:44Z

NEM ID 

Penneo dokumentnøgle: PQ4FV-K5KPM-V6EQM-0A1YB-Q6ZEA-I6O2W

Dette dokument er underskrevet digitalt via **Penneo.com**. Signeringsbeviserne i dokumentet er sikret og valideret ved anvendelse af den matematiske hashværdi af det originale dokument. Dokumentet er låst for ændringer og tidsstempelt med et certifikat fra en betroet tredjepart. Alle kryptografiske signeringsbeviser er indlejret i denne PDF, i tilfælde af de skal anvendes til validering i fremtiden.

### Sådan kan du sikre, at dokumentet er originalt

Dette dokument er beskyttet med et Adobe CDS certifikat. Når du åbner dokumentet

i Adobe Reader, kan du se, at dokumentet er certificeret af **Penneo e-signature service** <penneo@penneo.com>. Dette er din garanti for, at indholdet af dokumentet er uændret.

Du har mulighed for at efterprøve de kryptografiske signeringsbeviser indlejret i dokumentet ved at anvende Penneos validator på følgende websted: <https://penneo.com/validate>